Pharmaceuticals

T&K released FY2025 Q4 earnings on April 27 After-Market (BJT), actual revenue CNY 149.07 M, actual EPS CNY -0.0095

T&K released FY2025 annual earnings on April 27 After-Market (BJT), actual revenue CNY 674.9 M (forecast CNY 941 M), actual EPS CNY 0.07 (forecast CNY 0.6)

T&K released FY2026 Q1 earnings on April 27 After-Market (BJT), actual revenue CNY 189.52 M, actual EPS CNY 0.07

T&K to Release FY2026 Q1 Earnings Report on April 28 After-Market (BJT)

T&K to Release FY2025 Annual Earnings on April 28 After-Market (BJT), Forecast Revenue CNY 941 M, EPS CNY 0.6

T&K released FY2025 Q3 earnings on October 28 During-Market (BJT), actual revenue CNY 178.75 M, actual EPS CNY -0.0108

T&K released FY2025 9 Months Earnings on October 28 During-Market (BJT), Actual Revenue: CNY 525.83 M, Actual EPS: CNY 0.0739

T&K FY2025 Q3 Earnings Release on October 29, 2025 During-Market (BJT)

T&K released FY2025 Q2 earnings on August 20 After-Market (BJT), actual revenue CNY 162.42 M, actual EPS CNY 0.0148

T&K released FY2025 Semi-Annual Earnings on August 20 After-Market (BJT), with actual revenue of CNY 347.08 M and EPS of CNY 0.09

T&K to Release FY2025 Semi-Annual Earnings on August 21, 2025 (BJT)

Taiankang Subsidiary Completes Phase II Clinical Trial Data Unblinding for CKBA Ointment

Taikang's CKBA Ointment for Rosacea Enters Clinical Trials

Tiankang's CKBA cream Phase II clinical trial results expected to be released by the end of July

Tain Kang's stock price surge due to potential of innovative drug

Huazheng Index Releases Tanencom's ESG Rating

Tuankang's Wholly-Owned Subsidiary Huabokaiseng Receives Acceptance for Pinacidil Eye Drops Registration Application

Huayuan Securities Gives a Buy Rating to Taikang

Taikang Reveals Product Layout in Elderly Chronic Disease Field

Taienkang's Pilocarpine Hydrochloride Eye Drops Phase III Clinical Trial Completed

301263

T&K's wholly-owned subsidiary Huabo Kaisheng Biotechnology Co., Ltd. participated in the bidding for the 11th batch of national centralized drug procurement and is expected to be selected. The proposed selection prices for Huabo Kaisheng's Fumaric Acid Lurasidone Tablets and Alendronate Sodium Tablets are 30.49 yuan/box and 6.2 yuan/box, respectively, suitable for the treatment of allergic rhinitis, urticaria, and osteoporosis

Zhitong

T&K: Wholly-owned subsidiary Huabo Kaisheng intends to win the bid for the national centralized procurement of drugs

T&K announced that the revenue for the third quarter was 179 million yuan, an increase of 1.02%; the net profit loss was 5.6796 million yuan, a decrease of 118.57%. The revenue for the first three quarters was 526 million yuan, a decrease of 8.13%; the net profit was 31.4052 million yuan, a decrease of 73.00%

T&K: Net profit loss of 5.6796 million yuan in the third quarter, a decrease of 118.57%

According to the Zhitong Finance APP, T&K announced that its holding subsidiary Jiangsu Bochuangyuan Biomedical Technology Co., Ltd. (referred to as "Bochuangyuan") has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, agreeing to conduct a seamless adaptive clinical trial for CKBA cream for the indication of rosacea in Phase II/III

T&K: CKBA cream for rosacea indications to conduct seamless Phase II/III adaptive clinical trials

T&K announced that its wholly-owned subsidiary Anhui T&K Pharmaceutical Co., Ltd. has received the acceptance notice for the drug registration application for Safinamide Mesylate Tablets issued by the National Medical Products Administration. This drug is a selective inhibitor of monoamine oxidase B (MAO-B) and is primarily used for the treatment of adult patients with idiopathic Parkinson's disease as an adjunct therapy to levodopa

T&K: The drug registration application for Methanesulfonic Acid Safinamide Tablets has been accepted

According to the Zhitong Finance APP, T&K announced that its wholly-owned subsidiary Anhui T&K Pharmaceutical Co., Ltd. recently received the "Acceptance Notice" for the domestic production drug registration application for Dienogest Tablets issued by the National Medical Products Administration. Dienogest, as a selective progestin, is used to treat endometriosis, alleviating pain symptoms and stabilizing endometrial tissue, with advantages of good tolerance and low adverse reaction rates

T&K: The application for the domestic production drug registration and marketing license of Dydrogesterone Tablets has been accepted

T&K released its semi-annual report for 2025, with operating revenue of 347 million yuan, a year-on-year decrease of 12.23%; net profit attributable to the parent company was 37.0848 million yuan, a year-on-year decrease of 56.75%; net profit excluding non-recurring gains and losses was 36.8806 million yuan, a year-on-year decrease of 56.30%; basic earnings per share were 0.09 yuan

T&K released its performance for the first half of the year, with a net profit attributable to the parent company of 37.0848 million yuan, a year-on-year decrease of 56.75%

T&K plans to implement an employee stock ownership plan in 2025, with no more than 150 participants and a shareholding scale not exceeding 4.9751 million shares, aiming to raise a maximum of 200 million yuan. The duration of the plan is 36 months, with a lock-up period of 12 months, and the source of the shares will be through legal means such as purchases in the secondary market

T&K plans to launch an employee stock ownership plan in 2025, with a shareholding scale not exceeding 4.9751 million shares

T&K Holdings' subsidiary Bochuangyuan's CKBA ointment has achieved preliminary results in Phase II clinical trials for vitiligo, showing good efficacy and safety, meeting the expected goals. These results support the continuation of Phase III clinical trials and will be submitted to the CDE for breakthrough therapy application. As the first innovative drug targeting the T cell fatty acid metabolism pathway, CKBA demonstrates development potential in the field of autoimmune diseases. The company will accelerate the advancement of related clinical trials and basic research

T&K's subsidiary CKBA's ointment for vitiligo indications has obtained preliminary results from Phase II clinical trials and met the expected goals

T&K announced that its wholly-owned subsidiary Shandong Huabo Kaisheng Biotechnology Co., Ltd. recently received the Drug Registration Certificate for Alendronate Sodium Tablets issued by the National Medical Products Administration. Alendronate Sodium Tablets are indicated for the treatment of osteoporosis to prevent hip and spinal fractures, as well as for the treatment of glucocorticoid-induced osteoporosis, among others. A total of 24 companies in China have obtained the registration approval for this drug

T&K: Wholly-owned subsidiary receives drug registration certificate for Alendronate Sodium Tablets

T&K announced that its wholly-owned subsidiary Huabo Kaisheng has received the "Acceptance Notice" for the domestic production drug registration application for Pilocarpine Hydrochloride Eye Drops issued by the National Medical Products Administration. This drug is classified as a chemical drug category 3, with a specification of 1.25%, and the applicant is Huabo Kaisheng. Pilocarpine Hydrochloride Eye Drops can treat presbyopia in adults, and the original drug was developed by Allergan and has not yet been marketed domestically. Huabo Kaisheng is the first company in China to apply for and have the generic drug application for this product accepted

T&K(301263.SZ)